Antidepressant Manufacturers’ Trial Information Requested By Senate Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Chairman Grassley asks eight manufacturers for list of all pediatric antidepressant trials, including completion, publication and FDA submission information. Grassley expresses concern that the firms may not have provided FDA with all the information “at their disposal.”
You may also be interested in...
FDA Should Issue Pediatric Antidepressant Trial Summaries, Rep. Waxman Says
The congressman's letter requests the immediate release of data for drugs that gained six months of additional exclusivity under the Best Pharmaceuticals for Children Act. While seven companies have gained exclusivity extensions for antidepressants, data on only two are available, he says.
Grassley Expands FDA Drug Safety Inquiry
Senate Finance Committee Chairman Chuck Grassley (R-Iowa) has requested that the General Accounting Office review the relationship between FDA's Office of Drug Safety and Office of New Drugs
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.